Myelofibrosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MYELOF MCID: MYL005 MIFTS: 71	Myelofibrosis (MYELOF) Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Myelofibrosis

MalaCards integrated aliases for Myelofibrosis:

Name: Myelofibrosis ⁵⁷ ¹¹ ⁷⁵ ⁷³ ²⁸ ⁵³ ⁵ ¹⁴ ³⁶ ³⁸ ⁷¹

Primary Myelofibrosis ¹¹ ¹⁹ ⁴² ⁵⁸ ²⁸ ⁵³ ⁵ ⁴³ ¹⁶ ⁷¹ ⁷⁵ ³³

Agnogenic Myeloid Metaplasia ¹¹ ¹⁹ ⁴² ⁵⁸ ⁷³ ⁵³

Idiopathic Myelofibrosis ¹⁹ ⁴² ⁵⁸ ⁷³ ⁵³

Myeloid Metaplasia ¹⁹ ⁴² ⁵³ ⁷¹

Myelofibrosis with Myeloid Metaplasia ⁴² ⁵⁸ ⁷³

Osteomyelofibrosis ⁵⁸ ⁷¹ ³¹

Chronic Idiopathic Myelofibrosis ⁴² ³³

Megakaryocytic Myelosclerosis ¹¹ ⁷¹

Myelofibrosis, Idiopathic ⁷⁵ ¹²

Myelosclerosis ¹¹ ⁷³

Agnogenic Myeloid Metaplasia with Myelofibrosis ⁷³

Myelofibrosis with Myeloid Metaplasia, Somatic ⁵⁷

Myelosclerosis with Myeloid Metaplasia ⁷³

Myelofibrosis, Somatic ⁵⁷

Bone Marrow Fibrosis ¹¹

Aleukemic Myelosis ¹¹

Myelofibrosis Nos ³³

Myelof ⁷³

Ammm ⁷³

Mmm ⁷³

Characteristics:

Inheritance:

Somatic mutation ⁵⁷

Prevelance:

Primary Myelofibrosis: 1-9/100000 (Europe, Europe) ⁵⁸

Age Of Onset:

Primary Myelofibrosis: Adult ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
onset first weeks of life

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Neoplasms of uncertain or unknown behaviour

Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue

Osteomyelofibrosis

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Myeloproliferative neoplasms

Non mast cell myeloproliferative neoplasms

Primary myelofibrosis

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:4971

OMIM® ⁵⁷ 254450

ICD9CM ³⁴ 238.76 289.83

MeSH ⁴³ D009191 D055728

NCIt ⁴⁹ C2862 C3248

SNOMED-CT ⁶⁸ 128843003 267572005

ICD10 ³¹ D47.4

ICD10 via Orphanet ³² D47.4

UMLS via Orphanet ⁷² C0001815 C0026987

Orphanet ⁵⁸ ORPHA824

MedGen ⁴⁰ C0001815 C0026987

EFO ¹⁶ EFO_0002430

ICD11 ³³ 336704235

UMLS ⁷¹ C0001815 C0026987 C0027013 more

Sources

Summaries for Myelofibrosis

MedlinePlus Genetics: ⁴² Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.Because blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain.Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.

MalaCards based summary: Myelofibrosis, also known as primary myelofibrosis, is related to acute megakaryocytic leukemia and thrombocytosis. An important gene associated with Myelofibrosis is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Panobinostat and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and bone, and related phenotypes are fatigue and anemia

GARD: ¹⁹ Primary myelofibrosis is characterized by the buildup of scar tissue (fibrosis) in the spongy tissue tissue inside the bone (bone marrow). The spongy tissue inside bone contains the stem cells that will produce blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. This may lead to anemia, weakness, fatigue, and often, swelling of the liver and spleen. The disorder occurs when blood stem cells develop somatic genetic changes in the JAK2, MPL, CALR, and TET2 genes. Other genes may also be involved. The disorder is generally not inherited because this type of genetic change does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic).

UniProtKB/Swiss-Prot ⁷³ Myelofibrosis: A disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Myelofibrosis with myeloid metaplasia: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.

Orphanet: ⁵⁸ A rare myeloproliferative neoplasm characterized by stem-cell derived clonal over proliferation of mature myeloid lineages, such as erythrocytes, leukocytes, and megakaryocytes, with variable degrees of megakaryocyte atypia, associated with reticulin and/or collagen bone marrow fibrosis, osteosclerosis, ineffective erythropoiesis, angiogenesis, extramedullary hematopoiesis, and abnormal cytokine expression.

Disease Ontology: ¹¹ A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

Wikipedia: ⁷⁵ Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. It is classified by the World Health... more...

More information from OMIM: 254450

Sources

Related Diseases for Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 795)

#	Related Disease	Score	Top Affiliating Genes
1	acute megakaryocytic leukemia	32.5	THPO MPL KIT JAK2 GATA1
2	thrombocytosis	31.9	THPO TET2 MPL JAK2 EPO CD177
3	myeloproliferative neoplasm	31.9	THPO TET2 SH2B3 MPL KIT JAK2
4	splenomegaly	31.9	MPL JAK2 INSL6 EPO
5	thrombocytopenia	31.9	THPO SRC MPL MPIG6B KIT JAK2
6	pancytopenia	31.8	THPO MPL MPIG6B KIT EPO
7	thrombocythemia 1	31.8	THPO SH2B3 MPL CALR
8	polycythemia vera	31.7	THPO TET2 SRC MPL KIT JAK2
9	myelodysplastic syndrome	31.7	THPO TET2 MPL MEG3 KIT JAK2
10	aplastic anemia	31.6	THPO MPL GATA1 EPO
11	acute leukemia	31.6	THPO MPL KIT JAK2 GATA1 EPO
12	essential thrombocythemia	31.5	THPO TET2 SH2B3 MPL MIR223 KIT
13	deficiency anemia	31.4	THPO SH2B3 MPL KIT JAK2 GATA1
14	polycythemia	31.3	THPO TET2 SH2B3 MPL JAK2 INSL6
15	neutropenia	31.3	THPO MPL JAK2 EPO CD177
16	refractory anemia	31.2	TET2 MPL EPO
17	myelophthisic anemia	31.1	TET2 SH2B3 MPL JAK2 EPO CALR
18	mastocytosis	31.1	TET2 KIT JAK2
19	leukemia, chronic myeloid	31.1	THPO TET2 SRC MPL MIR223 MEG3
20	systemic mastocytosis	31.0	TET2 KIT JAK2
21	wernicke encephalopathy	31.0	MPL JAK2 CALR
22	blood platelet disease	31.0	THPO TET2 MPL KIT JAK2 GATA1
23	hemoglobinuria	30.9	THPO MPL EPO
24	portal vein thrombosis	30.9	THPO MPL JAK2
25	myeloma, multiple	30.9	TET2 SH2B3 MEG3 JAK2 FGF2 EPO
26	acute erythroid leukemia	30.9	KIT JAK2 GATA1 EPO
27	hematologic cancer	30.8	THPO MPL MIR223 MIR146B KIT JAK2
28	acquired polycythemia	30.8	MPL JAK2 EPO CALR
29	chronic myelomonocytic leukemia	30.8	TET2 SH2B3 MPL KIT JAK2 CALR
30	peripheral nervous system disease	30.8	SRC KIT JAK2 FGF2 EPO
31	splenic sequestration	30.6	THPO MPL EPO
32	chronic neutrophilic leukemia	30.6	TET2 JAK2 CALR
33	leukemia, chronic lymphocytic	30.5	THPO TET2 SRC MIR223 MIR146B KIT
34	myelodysplastic/myeloproliferative neoplasm	30.5	TET2 KIT JAK2 CALR
35	leukemia, acute lymphoblastic	30.5	THPO MPL MIR223 KIT JAK2 GATA1
36	diamond-blackfan anemia	30.4	THPO MPL KIT JAK2 GATA1 EPO
37	leukemia, acute myeloid	30.4	WT1-AS THPO TET2 SRC MPL MIR223
38	bone marrow cancer	30.4	THPO TET2 MPL MIR146B KIT JAK2
39	budd-chiari syndrome	30.3	MPL JAK2 INSL6 CALR
40	wilms tumor 1	30.3	WT1-AS TET2 MEG3 KIT
41	atypical chronic myeloid leukemia, bcr-abl1 negative	30.2	TET2 JAK2 CALR
42	chronic leukemia	30.2	TET2 KIT JAK2
43	beta-thalassemia major	30.2	GATA1 EPO BMP6
44	rasopathy	30.1	SRC KIT JAK2 FGF2
45	glioma	30.1	MIR146B MEG3 FGF2 CDKN2B-AS1 BMP6
46	acquired von willebrand syndrome	30.1	JAK2 CALR
47	acute promyelocytic leukemia	30.1	TET2 MIR223 MIR146B KIT GATA1
48	thrombocytopenia 1	30.1	THPO GATA1
49	chronic eosinophilic leukemia	30.1	TET2 SH2B3 MPL KIT JAK2 CALR
50	connective tissue disease	30.0	SRC MIR223 MIR146B KIT JAK2 FGF2

Graphical network of the top 20 diseases related to Myelofibrosis:

Sources

Symptoms & Phenotypes for Myelofibrosis

Human phenotypes related to Myelofibrosis:

⁵⁸ ³⁰ (show all 39)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
2	anemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001903
3	pallor ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000980
4	thrombocytopenia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001873
5	hepatosplenomegaly ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001433
6	abnormal megakaryocyte morphology ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012143
7	portal hypertension ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001409
8	venous thrombosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004936
9	easy fatigability ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003388
10	anorexia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002039
11	petechiae ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000967
12	arterial thrombosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004420
13	lymphadenopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002716
14	pancytopenia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001876
15	leukocytosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001974
16	low-grade fever ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011134
17	thrombocytosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001894
18	ecchymosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031364
19	extramedullary hematopoiesis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001978
20	poikilocytosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004447
21	bone marrow hypercellularity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031020
22	flank pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030157
23	cachexia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0004326
24	hemangioma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001028
25	hematological neoplasm ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0004377
26	increased circulating lactate dehydrogenase concentration ³⁰	Very rare (1%)		HP:0025435
27	splenomegaly ⁵⁸ ³⁰		Frequent (79-30%)	HP:0001744
28	fever ⁵⁸ ³⁰		Occasional (29-5%)	HP:0001945
29	purpura ⁵⁸ ³⁰		Occasional (29-5%)	HP:0000979
30	hepatomegaly ⁵⁸		Frequent (79-30%)
31	abnormal bleeding ⁵⁸		Occasional (29-5%)
32	abnormality of bone marrow cell morphology ⁵⁸		Very frequent (99-80%)
33	abnormality of blood and blood-forming tissues ⁵⁸		Frequent (79-30%)
34	myelofibrosis ³⁰			HP:0011974
35	myeloproliferative disorder ³⁰			HP:0005547
36	increased lactate dehydrogenase activity ⁵⁸		Very rare (<4-1%)
37	autoimmune antibody positivity ⁵⁸		Excluded (0%)
38	constitutional symptom ⁵⁸		Frequent (79-30%)
39	abnormal thrombosis ⁵⁸		Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Hematology:
myeloproliferative disease
reduced hemopoiesis
generalized bone marrow fibrosis
no hemophagocytosis

Clinical features from OMIM®:

254450 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Myelofibrosis according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in HMC1.1 cells	GR00105-A-0	8.62	KIT SRC

MGI Mouse Phenotypes related to Myelofibrosis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.1	CALR EPO FGF2 GATA1 INSL6 JAK2
2	immune system	MP:0005387	9.97	CD177 EPO GATA1 JAK2 KIT MIR146B
3	respiratory system	MP:0005388	9.61	EPO GATA1 JAK2 KIT MEG3 MIR223
4	hematopoietic system	MP:0005397	9.5	BMP6 CD177 EPO FGF2 GATA1 JAK2

Sources

Drugs & Therapeutics for Myelofibrosis

Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Panobinostat

Approved, Investigational

Phase 4

404950-80-7

6918837

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Histone Deacetylase Inhibitors

Phase 4

Pharmaceutical Solutions

Phase 4

Peginterferon alfa-2a

Approved, Investigational

Phase 3

198153-51-4

Pomalidomide

Approved

Phase 3

19171-19-8

134780

Thalidomide

Approved, Investigational, Withdrawn

Phase 3

50-35-1

5426

Orange

Approved

Phase 3

Alemtuzumab

Approved, Investigational

Phase 2, Phase 3

216503-57-0

Peginterferon alfa-2b

Approved

Phase 3

215647-85-1, 99210-65-8

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Mycophenolic acid

Approved, Investigational

Phase 3

24280-93-1

446541

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Apixaban

Approved

Phase 3

503612-47-3

10182969

Acetylsalicylic acid

Approved, Vet_approved

Phase 3

50-78-2

2244

Luspatercept

Approved, Investigational

Phase 3

1373715-00-4

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Rivaroxaban

Approved

Phase 3

366789-02-8

9875401

Danazol

Approved

Phase 3

17230-88-5

28417

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2, Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Imetelstat

Investigational

Phase 3

868169-64-6

Angiogenesis Inhibitors

Phase 3

Interferon alpha-2

Phase 3

Interferon-alpha

Phase 3

Adjuvants, Immunologic

Phase 3

Anti-Bacterial Agents

Phase 3

Anti-Infective Agents

Phase 3

Cyclooxygenase Inhibitors

Phase 3

Anti-Inflammatory Agents, Non-Steroidal

Phase 3

Androgens

Phase 2, Phase 3

Analgesics, Non-Narcotic

Phase 3

Anti-Inflammatory Agents

Phase 3

Analgesics

Phase 3

Antibiotics, Antitubercular

Phase 3

Antitubercular Agents

Phase 3

Fibrinolytic Agents

Phase 3

Antipyretics

Phase 3

Platelet Aggregation Inhibitors

Phase 3

Anticoagulants

Phase 3

Hematinics

Phase 3

Motesanib diphosphate

Phase 3

Citrate

Phase 3

Estrogens

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hepcidins

Phase 3

Janus Kinase Inhibitors

Phase 3

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Interventional clinical trials:

(show top 50) (show all 369)

#	Name	Status	NCT ID	Phase	Drugs
1	A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)	Completed	NCT01558739	Phase 4	INC424
2	Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies	Recruiting	NCT02386800	Phase 4	ruxolitinib;panobinostat
3	A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study	Recruiting	NCT05447260	Phase 4	Ruxolitinib
4	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib	Completed	NCT02101268	Phase 3	Momelotinib;Best Available Therapy (BAT)
5	A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis	Completed	NCT02087059	Phase 3	Ruxolitinib
6	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
7	A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Completed	NCT01969838	Phase 3	Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
8	A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies	Completed	NCT00438958	Phase 3
9	A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis	Completed	NCT00934544	Phase 3	Ruxolitinib;Best Available Therapy (BAT)
10	A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators	Completed	NCT00235391	Phase 3	Deferasirox
11	A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis	Completed	NCT00952289	Phase 3	Ruxolitinib;Placebo
12	An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).	Completed	NCT01493414	Phase 3	INC424
13	Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)	Completed	NCT01428635	Phase 2, Phase 3	Eltrombopag Olamine
14	Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.	Completed	NCT01387763	Phase 3	PegIntron;Pegasys;Hydrea
15	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly	Completed	NCT01437787	Phase 3	SAR302503;Placebo
16	A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence	Completed	NCT01178281	Phase 3	Pomalidomide 0.5 mg;Placebo;Pomalidomide
17	Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors	Completed	NCT00354120	Phase 2, Phase 3	Alentuzumab;Globulina antilinfocitaria
18	A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis	Recruiting	NCT04617028	Phase 3	Jaktinib;Placebo to match Hydroxycarbamide;Hydroxycarbamide Tablets;Placebo to match Jaktinib
19	A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions	Recruiting	NCT04717414	Phase 3	ACE-536
20	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor	Recruiting	NCT04576156	Phase 3	Imetelstat;Best Available Therapy (BAT)
21	A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib	Recruiting	NCT04551053	Phase 3	parsaclisib;ruxolitinib;placebo
22	A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients	Recruiting	NCT04603495	Phase 3	Pelabresib;Ruxolitinib;Placebo
23	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis	Recruiting	NCT04551066	Phase 3	parsaclisib;ruxolitinib;placebo
24	A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment	Recruiting	NCT03662126	Phase 2, Phase 3	KRT-232;Best Available Therapy (BAT)
25	A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials	Recruiting	NCT04064060	Phase 3	Luspatercept
26	A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)	Recruiting	NCT03165734	Phase 3	Pacritinib;Physician's Choice medications
27	AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms	Recruiting	NCT05198960	Phase 3	Direct Oral Anticoagulants;Low-dose aspirin
28	A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)	Recruiting	NCT04468984	Phase 3	Navitoclax;Ruxolitinib;Best Available Therapy (BAT)
29	A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib	Recruiting	NCT03952039	Phase 3	FEDRATINIB;Best Available Therapy (BAT)
30	Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression	Recruiting	NCT03480360	Phase 3	Cyclophosphamide;Fludarabine;Tacrolimus;cellcept;g-csf
31	A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib	Active, not recruiting	NCT03755518	Phase 3	FEDRATINIB
32	A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy	Active, not recruiting	NCT04173494	Phase 3	Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
33	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)	Active, not recruiting	NCT04472598	Phase 3	Navitoclax;Ruxolitinib;Placebo for Navitoclax
34	A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations	Terminated	NCT02598297	Phase 3	Ruxolitinib;Ruxolitinib Placebo
35	A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Terminated	NCT02055781	Phase 3	Pacritinib;Best Available Therapy
36	A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	Terminated	NCT01773187	Phase 3	Pacritinib;Best Available Therapy
37	A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis	Unknown status	NCT00668421	Phase 1, Phase 2	CEP-701 (Lestaurtinib)
38	A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Unknown status	NCT01298934	Phase 1, Phase 2	LBH589
39	An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis	Completed	NCT00724334	Phase 1, Phase 2	SAR302503 (TG101348)
40	A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)	Completed	NCT01981850	Phase 2	Ruxolitinib
41	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
42	A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly	Completed	NCT01692366	Phase 2	SAR302503
43	Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial	Completed	NCT00397813	Phase 2	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
44	A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®	Completed	NCT00669578	Phase 1, Phase 2	CC-4047
45	Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis	Completed	NCT02267278	Phase 2	Ruxolitinib;Pracinostat
46	Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	Completed	NCT02742324	Phase 1, Phase 2	Ruxolotinib;peg-IFN alpha -2a
47	Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)	Completed	NCT02065154	Phase 2	Cyclophosphamide
48	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
49	Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning	Completed	NCT00475020	Phase 2	Busulfan;Fludarabine;Thymoglobulin (ATG)
50	A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis	Completed	NCT02718300	Phase 2	Parsaclisib;Ruxolitinib

Search NIH Clinical Center for Myelofibrosis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Busulfan

ruxolitinib

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Myelofibrosis cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Myelofibrosis:

Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis

Embryonic/Adult Cultured Cells Related to Myelofibrosis:

Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: primary myelofibrosis

Sources

Genetic Tests for Myelofibrosis

Genetic tests related to Myelofibrosis:

#	Genetic test	Affiliating Genes
1	Myelofibrosis ²⁸	CALR JAK2 MPL SH2B3
2	Primary Myelofibrosis ²⁸

Sources

Anatomical Context for Myelofibrosis

Organs/tissues related to Myelofibrosis:

MalaCards : Bone Marrow, Myeloid, Bone, Spleen, Liver, T Cells, Kidney

Sources

Publications for Myelofibrosis

Articles related to Myelofibrosis:

(show top 50) (show all 8552)

#	Title	Authors	PMID	Year
1	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. ⁶² ⁵⁷ ⁵	Pardanani AD...Tefferi A	16868251	2006
2	MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. ⁶² ⁵⁷ ⁵	Pikman Y...Levine RL	16834459	2006
3	A gain-of-function mutation of JAK2 in myeloproliferative disorders. ⁶² ⁵⁷ ⁵	Kralovics R...Skoda RC	15858187	2005
4	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. ⁵⁷ ⁵	Arranz L...Mendez-Ferrer S	25043017	2014
5	Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. ⁵⁷ ⁵	Mendez-Ferrer S...Frenette PS	20703299	2010
6	Haematopoietic stem cell release is regulated by circadian oscillations. ⁵⁷ ⁵	Mendez-Ferrer S...Frenette PS	18256599	2008
7	Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. ⁵³ ⁶² ⁵	Boyd EM...Erber WN	20151976	2010
8	New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. ⁵³ ⁶² ⁵	Chaligne R...Giraudier S	18528423	2008
9	V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. ⁵³ ⁶² ⁵	Campbell PJ...Reilly JT	16293597	2006
10	The JAK2 V617F mutation in de novo acute myelogenous leukemias. ⁵³ ⁶² ⁵	Lee JW...Lee SH	16247455	2006
11	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. ⁵³ ⁶² ⁵	Campbell PJ...Australasian Leukaemia and Lymphoma Group	16325696	2005
12	Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. ⁵³ ⁶² ⁵⁷	Baxter EJ...Cancer Genome Project	15781101	2005
13	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. ⁶² ⁵	Rumi E...Cazzola M	24986690	2014
14	JAK inhibitor in CALR-mutant myelofibrosis. ⁶² ⁵⁷	Passamonti F...Maffioli M	24645956	2014
15	JAK inhibitor in CALR-mutant myelofibrosis. ⁶² ⁵⁷	Cazzola M...Kralovics R	24645955	2014
16	Somatic mutations of calreticulin in myeloproliferative neoplasms. ⁶² ⁵	Klampfl T...Kralovics R	24325356	2013
17	Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. ⁶² ⁵	Nangalia J...Green AR	24325359	2013
18	Familial idiopathic myelofibrosis and multiple hemangiomas. ⁶² ⁵⁷	Bonduel M...Gallo G	9766805	1998
19	Familial myelofibrosis. ⁶² ⁵⁷	Sieff CA...Malleson P	7436463	1980
20	Whole-genome sequencing of patients with rare diseases in a national health system. ⁵	Turro E...Ouwehand WH	32581362	2020
21	Effect of mutation order on myeloproliferative neoplasms. ⁵	Ortmann CA...Green AR	25671252	2015
22	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
23	Interferon alfa therapy in CALR-mutated essential thrombocythemia. ⁵⁷	Cassinat B...Kiladjian JJ	25006741	2014
24	MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. ⁵⁷	Jutzi JS...Pahl HL	23589569	2013
25	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. ⁵⁷	Kaufmann KB...Pahl HL	22231305	2012
26	A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. ⁵	Jalas C...Rubin BY	21489838	2011
27	Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. ⁵	Oh ST...Gotlib J	20404132	2010
28	MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. ⁶² ⁴⁶	Hussein K...Bock O	19811223	2009
29	Mutation in TET2 in myeloid cancers. ⁵⁷	Delhommeau F...Bernard OA	19474426	2009
30	The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. ⁵	Sozer S...Hoffman R	19293426	2009
31	No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. ⁵	Dahabreh IJ...Zoi K	19036091	2009
32	JAK2 V617F mutation in unexplained loss of first pregnancy. ⁵	Mercier E...Gris JC	17989398	2007
33	Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. ⁵	Patel RK...Mufti GJ	16762626	2006
34	Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. ⁵	Chung RT...Misdraji J	16707754	2006
35	The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. ⁵	Jamieson CH...Weissman IL	16603627	2006
36	MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. ⁵	Germeshausen M...Welte K	16470591	2006
37	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. ⁵	James C...Vainchenker W	15793561	2005
38	Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. ⁵³ ⁶²	Glembotsky AC...Heller PG	20113333	2010
39	Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. ⁵³ ⁶²	Gualco G...Bacchi CE	20042850	2010
40	Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. ⁵³ ⁶²	Koppikar P...Levine RL	20154217	2010
41	Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. ⁵³ ⁶²	Verstovsek S	20215535	2010
42	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. ⁵³ ⁶²	Tefferi A	20214447	2010
43	JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. ⁵³ ⁶²	Siemiatkowska A...Limon J	19643476	2010
44	MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes. ⁵³ ⁶²	Ruan GR...Chen SS	19274616	2010
45	Therapy of myelofibrosis (excluding JAK2 inhibitors). ⁵³ ⁶²	Rambaldi A	20178012	2010
46	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. ⁵³ ⁶²	Santos FP...Verstovsek S	20008298	2010
47	Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation. ⁵³ ⁶²	Meyer T...Neubauer A	20013324	2010
48	JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. ⁵³ ⁶²	Tefferi A...Pardanani A	19847199	2010
49	Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor. ⁵³ ⁶²	Kikukawa M...Iwamoto T	20002760	2009
50	Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. ⁵³ ⁶²	Kiss R...Keseru GM	19447617	2009

Sources

Genes for Myelofibrosis

Genes related to Myelofibrosis (6 elite genes):

(show top 50) (show all 93)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MPL	MPL Proto-Oncogene, Thrombopoietin Receptor	Protein Coding	1737.89	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative somatic mutation ⁵⁸ Causative variation ⁷³ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	16470591 16834459 16868251 (more) 21489838 20151976 18528423 11007052 11012187 9592015 17920755 17408465 17133099 9864154 15095485 19194467 20113333 8589367
2	JAK2	Janus Kinase 2	Protein Coding	1447.17	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative somatic mutation ⁵⁸ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	15858187 15793561 16603627 (more) 16325696 18256599 20703299 25043017 25671252 16247455 17989398 19036091 16707754 16762626 19293426 16293597 25157968 24986690 32581362 16456374 17133423 16673274 16418333 16871275 16007902 16901656 20215535 19669209 18394555 19287382 20425436 16285006 18612778 16373657 20154217 18786436 17885079 20008298 20178012 17162218 18612101 17145024 20151976 17183644 18850308 19387008 17213018 17317861 17875526 16645202 17764814 16357566 17920755 17077140 18088495 17262192 17643100 16959246 15781101 19643476 18220909 17267906 16502590 20425335 20042850 16877349 20013324 16912229 16155011 17030374 17605888 18032973 17361221 20008249 18429051 19175693 17488875 18618714 19147089 19778861 19847199 17706283 19713696 17907502 18841497 18575049 19468275 20214447 19447617 18314608 17906464
3	CALR	Calreticulin	Protein Coding	1377.23	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative somatic mutation ⁵⁸ Genetic Tests ²⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	24325356 24325359 24325256
4	SH2B3	SH2B Adaptor Protein 3	Protein Coding	1007.28	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴	20404132
5	INSL6	Insulin Like 6	Protein Coding	429.15	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	15858187 15793561 16603627 (more) 16325696 18256599 20703299 25043017 25671252 16247455 17989398 19036091 16707754 16762626 19293426 16293597 25157968 24986690 32581362
6	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	374.84	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	19557078 19262601
7	WT1-AS	WT1 Antisense RNA	RNA Gene	159.81	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24707949
8	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	157.01	Experimental evidence: Expression ³⁷ GeneCards inferred via : Publications (show sections)	24707949
9	MEG3	Maternally Expressed 3	RNA Gene	157.01	Experimental evidence: Expression ³⁷ GeneCards inferred via : Publications (show sections)	24707949
10	MIR146B	MicroRNA 146b	RNA Gene	60.36	Unspecified ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19811223
11	THPO	Thrombopoietin	Protein Coding	54.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9626028 16115126 11012187 (more) 11379259 17473062 9373248 12479847 18669880 19274616 20113333 9163612 17374740 9614574 16456374 15085152 17488682 14560783 16034467 10776693 19099659
12	MIR223	MicroRNA 223	RNA Gene	53.44	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19811223
13	EPO	Erythropoietin	Protein Coding	51.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9718866 1588794 8355412 (more) 1378668 15521916 7918092 11391725 9647492 16532437 8435333 7847335 8175031 8701705 12886259 17159338 8285020 15693801 17077140 8417383 10146863 7986477 15725078 8779784 2290709 1460322
14	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	46.7	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	32581362
15	CD177	CD177 Molecule	Protein Coding	33.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16197445 17852451 12377969
16	FGF2	Fibroblast Growth Factor 2	Protein Coding	28.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8977245 12648509 8703817 (more) 9163611 12373082 11317961 15279663 11146571 10550553 12689941 18349123 14560783 20002760 10647876
17	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	27.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19175693 12580961 16155011 (more) 7512174
18	GATA1	GATA Binding Protein 1	Protein Coding	26.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12788793 16127162 12149188 (more) 17488682
19	BMP6	Bone Morphogenetic Protein 6	Protein Coding	26.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1901495 1998600 8977245 (more) 12648509 7803262 2317561 9766798 9432016 16034467 7488550 10647876 12688359 7741102 18342720 18349123
20	MPIG6B	Megakaryocyte And Platelet Inhibitory Receptor G6b	Protein Coding	22.88	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
21	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	22.72	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
22	HMGA2	High Mobility Group AT-Hook 2	Protein Coding	22.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14603445 17065012
23	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	21.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17376889
24	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	21.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12842707 7589339 17255768
25	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	20.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12580961 16155011
26	IFNA1	Interferon Alpha 1	Protein Coding	20.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9436922 7536475 2064955 (more) 11697640 10803930 10651725 9092696 10674896 14635203 14726401
27	FKBP5	FKBP Prolyl Isomerase 5	Protein Coding	20.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15089760 12842707 12351405
28	CSF3	Colony Stimulating Factor 3	Protein Coding	19.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8882966
29	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	19.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16109602 9359522 10938591 (more) 14667201
30	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	18.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9432016 18349123 15726648 (more) 8435322 10497847 16034467 11185990 15833861 16019489
31	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	18.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9680115
32	IFNA2	Interferon Alpha 2	Protein Coding	17.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2064955 2332985 2098307 (more) 9740087
33	IL3	Interleukin 3	Protein Coding	17.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8590852 7589339
34	ASXL1	ASXL Transcriptional Regulator 1	Protein Coding	16.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	JAK1	Janus Kinase 1	Protein Coding	16.64	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	SRSF2	Serine And Arginine Rich Splicing Factor 2	Protein Coding	15.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	CD34	CD34 Molecule	Protein Coding	15.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	15.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18206727
39	JAK3	Janus Kinase 3	Protein Coding	14.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	14.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	14.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	14.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	14.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
44	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	14.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	TNFRSF11B	TNF Receptor Superfamily Member 11b	Protein Coding	14.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15504545 15982347
46	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	14.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	13.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	13.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	EPOR	Erythropoietin Receptor	Protein Coding	13.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	TP53	Tumor Protein P53	Protein Coding	13.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Myelofibrosis

ClinVar genetic disease variations for Myelofibrosis:

⁵ (show all 11)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MPL	NM_005373.3(MPL):c.1543_1544delinsAA (p.Trp515Lys)	INDEL	Pathogenic	14165	rs121913616	GRCh37: 1:43815008-43815009 GRCh38: 1:43349337-43349338
2	SH2B3	NM_005475.3(SH2B3):c.603_607del (p.Arg202fs)	DEL	Pathogenic	30444	rs587776885	GRCh37: 12:111856549-111856553 GRCh38: 12:111418745-111418749
3	CALR	NM_004343.3(CALR):c.1092_1143del52 (p.Leu367Thrfs)	DEL	Pathogenic	97006	rs1555760738	GRCh37: 19:13054565-13054616 GRCh38: 19:12943751-12943802
4	MPL	NM_005373.3(MPL):c.1653+1del	DEL	Pathogenic	632897	rs755257605	GRCh37: 1:43817974-43817974 GRCh38: 1:43352303-43352303
5	MPL	NM_005373.3(MPL):c.1544G>T (p.Trp515Leu)	SNV	Pathogenic	14164	rs121913615	GRCh37: 1:43815009-43815009 GRCh38: 1:43349338-43349338
6	MPL	NM_005373.3(MPL):c.79+2T>A	SNV	Pathogenic Pathogenic	135563	rs146249964	GRCh37: 1:43803600-43803600 GRCh38: 1:43337929-43337929
7	JAK2, INSL6	NM_004972.4(JAK2):c.1849G>T (p.Val617Phe)	SNV	Pathogenic Pathogenic/Likely Pathogenic Likely Pathogenic	14662	rs77375493	GRCh37: 9:5073770-5073770 GRCh38: 9:5073770-5073770
8	SRC	NM_198291.3(SRC):c.1579G>A (p.Glu527Lys)	SNV	Likely Pathogenic	225689	rs879255268	GRCh37: 20:36031750-36031750 GRCh38: 20:37403347-37403347
9	overlap with 9 genes	NC_000014.8:g.96163103_96857129dup	DUP	Likely Pathogenic	208237		GRCh37: 14:96163103-96857129 GRCh38: 14:95696766-96390792
10	MPL	NM_005373.3(MPL):c.1514G>A (p.Ser505Asn)	SNV	Likely Pathogenic	14163	rs121913614	GRCh37: 1:43814979-43814979 GRCh38: 1:43349308-43349308
11	SH2B3	NM_005475.3(SH2B3):c.1198G>A (p.Glu400Lys)	SNV	Uncertain Significance	501686	rs72650673	GRCh37: 12:111885310-111885310 GRCh38: 12:111447506-111447506

UniProtKB/Swiss-Prot genetic disease variations for Myelofibrosis:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	MPL	p.Trp515Lys	VAR_067560	rs121913616
2	MPL	p.Trp515Leu	VAR_067561	rs121913615

Copy number variations for Myelofibrosis from CNVD:

⁶ (show top 50) (show all 1783)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13799	1	1	5300000	Copy-Neutral LOH	GABRD	Myelofibrosis
2	13967	1	102000000	107000000	Amplification without LOH	AMY2A	Myelofibrosis
3	13968	1	102000000	107000000	Deletion without LOH	COL11A1	Myelofibrosis
4	13969	1	102000000	107000000	Deletion without LOH	PRMT6	Myelofibrosis
5	14306	1	107000000	111600000	Amplification without LOH	GSTM1	Myelofibrosis
6	14307	1	107000000	111600000	Amplification without LOH	GSTM5	Myelofibrosis
7	14308	1	107000000	111600000	Amplification without LOH	KCNC4	Myelofibrosis
8	14310	1	107000000	111600000	Deletion without LOH	EEIG2	Myelofibrosis
9	14311	1	107000000	111600000	Deletion without LOH	NBPF6	Myelofibrosis
10	14313	1	107000000	111600000	Deletion without LOH	WDR47	Myelofibrosis
11	14960	1	111600000	115900000	Amplification without LOH	KCND3	Myelofibrosis
12	14961	1	111600000	115900000	Amplification without LOH	TRIM33	Myelofibrosis
13	14962	1	111600000	115900000	Deletion without LOH	CTTNBP2NL	Myelofibrosis
14	15472	1	115900000	117600000	Amplification without LOH	ATP1A1	Myelofibrosis
15	15473	1	115900000	117600000	Amplification without LOH	CASQ2	Myelofibrosis
16	15635	1	117600000	120700000	Deletion without LOH	PHGDH	Myelofibrosis
17	15636	1	117600000	120700000	Deletion without LOH	VTCN1	Myelofibrosis
18	15637	1	117600000	120700000	Deletion without LOH	ZNF697	Myelofibrosis
19	17279	1	142400000	148000000	Amplification without LOH	NOTCH2NLA	Myelofibrosis
20	18948	1	148000000	149600000	Amplification without LOH		Myelofibrosis
21	18949	1	148000000	149600000	Amplification without LOH	NBPF15	Myelofibrosis
22	18952	1	148000000	149600000	Deletion without LOH	FCGR1CP	Myelofibrosis
23	19322	1	149600000	153300000	Amplification without LOH	LCE1D	Myelofibrosis
24	19323	1	149600000	153300000	Amplification without LOH	LCE3C	Myelofibrosis
25	19324	1	149600000	153300000	Amplification without LOH	POGZ	Myelofibrosis
26	19325	1	149600000	153300000	Amplification without LOH	THEM5	Myelofibrosis
27	20607	1	153300000	154800000	Amplification without LOH	KCNN3	Myelofibrosis
28	20845	1	154800000	157300000	Amplification with LOH	MIR555	Myelofibrosis
29	20846	1	154800000	157300000	Deletion without LOH		Myelofibrosis
30	21201	1	157300000	158800000	Amplification without LOH	OR6N2	Myelofibrosis
31	21202	1	157300000	158800000	Amplification without LOH	OR6Y1	Myelofibrosis
32	21203	1	157300000	158800000	Deletion without LOH	CD5L	Myelofibrosis
33	21465	1	158800000	163800000	Amplification without LOH	CCDC190	Myelofibrosis
34	21466	1	158800000	163800000	Amplification without LOH	VSIG8	Myelofibrosis
35	21734	1	16100000	20300000	Amplification without LOH	ARHGEF10L	Myelofibrosis
36	21735	1	16100000	20300000	Amplification without LOH	NBPF1	Myelofibrosis
37	21736	1	16100000	20300000	Amplification without LOH	PAX7	Myelofibrosis
38	21737	1	16100000	20300000	Amplification without LOH	RCC2	Myelofibrosis
39	21738	1	16100000	20300000	Amplification without LOH	UQCRHL	Myelofibrosis
40	21740	1	16100000	20300000	Copy-Neutral LOH	ATP13A2	Myelofibrosis
41	21743	1	16100000	23800000	Copy-Neutral LOH	MRTO4	Myelofibrosis
42	22129	1	165500000	169100000	Amplification without LOH		Myelofibrosis
43	22130	1	165500000	169100000	Amplification without LOH	MIR921	Myelofibrosis
44	22131	1	165500000	169100000	Deletion without LOH	FMO9P	Myelofibrosis
45	22825	1	169100000	171200000	Amplification without LOH	NME7	Myelofibrosis
46	22829	1	169100000	171200000	Deletion without LOH	KIFAP3	Myelofibrosis
47	23058	1	171200000	174300000	Amplification without LOH	C1orf105	Myelofibrosis
48	23059	1	171200000	174300000	Deletion without LOH	PRRC2C	Myelofibrosis
49	23060	1	171200000	174300000	Deletion without LOH	DNM3	Myelofibrosis
50	23061	1	171200000	174300000	Deletion without LOH	SLC9C2	Myelofibrosis

Sources

Expression for Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Sources

Pathways for Myelofibrosis

Pathways related to Myelofibrosis according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.3	THPO SRC MPL KIT JAK2 FGF2
2	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	12.92	THPO SRC SH2B3 MPL MPIG6B JAK2
3	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.59	SRC SH2B3 KIT JAK2 FGF2
4	NF-kappaB Signaling ³	12.37	MPL KIT JAK2 GATA1
5	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.2	THPO SRC KIT JAK2 FGF2 EPO
6	Tyrosine Kinases / Adaptors ³	11.88	SRC KIT JAK2 FGF2
7	Gastrin signaling pathway ⁷⁴	11.77	SRC KIT JAK2
8	Visual Cycle in Retinal Rods ⁶⁴	11.72	THPO MPL JAK2
9	Integrin signaling ⁶⁶ Show member pathways GRB2:SOS provides linkage to MAPK signaling for Integrins ⁶⁶ p130Cas linkage to MAPK signaling for integrins ⁶⁶ Platelet Aggregation (Plug Formation) ⁶⁶	11.68	THPO SRC MPL
10	CCL18 signaling pathway ⁷⁴	11.67	SRC JAK2 FGF2
11	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.66	SRC SH2B3 KIT JAK2
12	Signaling by Erythropoietin ⁶⁶ Show member pathways EPO signaling pathway ⁶¹ Erythropoietin activates Phosphoinositide-3-kinase (PI3K) ⁶⁶ Erythropoietin activates Phospholipase C gamma (PLCG) ⁶⁶ Erythropoietin activates RAS ⁶⁶ Erythropoietin activates STAT5 ⁶⁶	11.65	SH2B3 JAK2 EPO
13	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.6	THPO KIT FGF2 BMP6
14	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.42	SRC SH2B3 KIT JAK2 EPO
15	Pluripotent stem cell differentiation pathway ⁷⁴	11.29	EPO FGF2 KIT
16	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.09	THPO SH2B3 MPL KIT EPO
17	Angiogenesis (WikiPathways) ⁷⁴	10.85	SRC FGF2
18	S1P3 pathway ⁶¹	10.71	SRC JAK2

Sources

GO Terms for Myelofibrosis

Biological processes related to Myelofibrosis according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of MAPK cascade	GO:0043410	10.19	THPO KIT JAK2 FGF2
2	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.11	SRC JAK2 GATA1 BMP6
3	positive regulation of gene expression	GO:0010628	10.1	BMP6 CALR CDKN2B-AS1 FGF2 KIT MIR223
4	positive regulation of cell population proliferation	GO:0008284	10.1	BMP6 CALR EPO FGF2 JAK2 KIT
5	cellular response to lipopolysaccharide	GO:0071222	10.09	THPO SRC MIR223 JAK2 GATA1
6	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.06	FGF2 JAK2 KIT SRC
7	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	10.03	SRC JAK2 FGF2
8	positive regulation of phosphatidylinositol 3-kinase activity	GO:0043552	10.01	SRC KIT FGF2
9	cell population proliferation	GO:0008283	9.97	THPO SRC KIT GATA1 FGF2
10	neutrophil homeostasis	GO:0001780	9.89	SH2B3 MPL
11	myeloid cell apoptotic process	GO:0033028	9.88	GATA1 EPO
12	cellular response to interleukin-3	GO:0036016	9.87	SH2B3 JAK2
13	erythropoietin-mediated signaling pathway	GO:0038162	9.85	EPO KIT
14	monocyte homeostasis	GO:0035702	9.83	SH2B3 MPL
15	megakaryocyte differentiation	GO:0030219	9.8	THPO MPIG6B GATA1
16	myeloid cell differentiation	GO:0030099	9.78	TET2 JAK2 GATA1
17	negative regulation of myeloid cell apoptotic process	GO:0033033	9.77	GATA1 EPO
18	embryonic hemopoiesis	GO:0035162	9.77	SH2B3 KIT GATA1
19	thrombopoietin-mediated signaling pathway	GO:0038163	9.63	THPO SH2B3 MPL
20	megakaryocyte development	GO:0035855	9.56	THPO SH2B3 MPIG6B KIT
21	erythrocyte differentiation	GO:0030218	9.32	MPIG6B KIT JAK2 GATA1 EPO